[New anti-arrhythmics--hope or disappointment?]

Area of Science:

• Pharmacology
• Cardiology
• Electrophysiology

Context:

• Recent advancements in anti-arrhythmic drug development focus on blocking repolarization currents (Class III action).
• Dronedarone, a derivative of amiodarone, exhibits multi-class anti-arrhythmic properties.
• Understanding the electrophysiological effects and clinical outcomes of these agents is crucial for managing cardiac arrhythmias.

Purpose:

• To review new anti-arrhythmic agents, particularly Class III drugs, and their mechanisms of action.
• To evaluate the efficacy and safety profiles of dofetilide, ibutilide, azimilide, and dronedarone in treating and preventing arrhythmias.
• To compare the risk-benefit ratios of these novel therapeutic options.

Summary:

• Pure Class III agents prolong the cardiac action potential and refractory period, primarily acting on re-entry arrhythmias by blocking the Ikr current.
• Dofetilide and ibutilide demonstrate efficacy in converting atrial tachyarrhythmias but carry a risk of torsades de pointe, necessitating hospital initiation.
• Azimilide shows sustained electrophysiological effects and good tolerance in paroxysmal atrial fibrillation, with a neutral survival effect in high-risk patients. Dronedarone offers moderate efficacy for atrial fibrillation prevention but is contraindicated in left ventricular dysfunction due to excess mortality risk.

Impact:

• Provides a comprehensive overview of novel anti-arrhythmic agents, aiding clinicians in selecting appropriate treatments.
• Highlights the importance of risk stratification and patient selection for drugs like dofetilide, ibutilide, and dronedarone.
• Contributes to the understanding of drug-induced proarrhythmia, particularly torsades de pointe, and informs clinical guidelines for arrhythmia management.